Table 3.
Women | Men | |||
---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | |
Antipsychotic | ||||
Aripiprazole (mg) | 3 | 6.7 ± 7.2 | 3 | 1.4 ± 0.8 |
Olanzapine (mg) | 3 | 9.2 ± 3.8 | — | — |
Quetiapine (mg) | 11 | 127.5 ± 191.3 | 10 | 107.5 ± 84.2 |
Risperidone (mg) | 3 | 1.8 ± 1.3 | 1 | 2 |
Quetiapine (mg)/risperidone (mg) | — | — | 1 | 400/1 |
Mood stabilizer | ||||
Lamotrigine (mg) | 5 | 47.5 ± 28.5 | 1 | 300 |
Lithium (mg) | 2 | 450 ± 212.1 | 1 | 600 |
Topiramate (mg) | 1 | 25 | — | — |
Valproic acid (mg) | 1 | 125 | 5 | 415.0 ± 213.3 |
Lamotrigine (mg)/valproic acid (mg) | — | — | 1 | 150/1250 |
Antipsychotic + mood stabilizer | ||||
Aripiprazole/lithium (mg) | 1 | 5/300 | — | — |
Aripiprazole/lamotrigine (mg) | 1 | 12.5/300 | — | — |
Aripiprazole/valproic acid (mg) | — | — | 3 | 2/ 375 ± 216.5 |
Olanzapine (mg)/lamotrigine (mg)/lithium (mg) | — | — | 1 | 5/ 50/300 |
Olanzapine (mg)/quetiapine (mg)/lithium (mg) | — | — | 1 | 5/ 300/300 |
Olanzapine (mg)/gabapentin (mg) | — | — | 1 | 15/600 |
Olanzapine (mg)/valproic acid (mg) | 2 | 5/250 | — | — |
Quetiapine (mg)/gabapentin (mg) | — | — | 1 | 50/600 |
Quetiapine (mg)/topiramate (mg) | — | — | 1 | 50/25 |
Quetiapine (mg)/gabapentin (mg) | 1 | 50/300 | 1 | 600/900 |
Quetiapine(mg)/lamotrigine (mg) | 2 | 50/ 122.5 ± 123.7 | — | — |
Quetiapine (mg)/valproic acid (mg) | 2 | 50/ 625 ± 530.3 | 2 | 125 ± 35.4/250 |
Quetiapine (mg)/gabapentin (mg)/valproic acid (mg) | 1 | 300/300/125 | — | — |
Quetiapine (mg)/topiramate (mg)/valproic acid (mg) | 1 | 125/25/125 | — | — |
Risperidone (mg)/valproic acid (mg) | 1 | 0.5/25 | — | — |
Therapeutic range: Aripiprazole [2–15 mg]; Olanzapine [5–20 mg]; Quetiapine [50–300 mg]; Risperidone [0.25–3 mg]; Lamotrigine [25–200 mg]; Lithium [600–1200 mg, based on therapeutic serum levels]; Topiramate [N/A]; Valproic Acid [N/A, based on therapeutic serum levels].